Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS

NCT04267536 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04267536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04267536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
February 6, 2020
Completion date
February 1, 2022
Enrollment
534 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)